Clinical trials: Geriatric Disorders
Influenza
Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 08/09 Season.
Influenza (flu) viruses change continuously, therefore also the parts of viruses used in influenza vaccines can vary from year to year.
- Trial name
- NCT00665509
- Testing
- Trivalent influenza subunit vaccine Influvac
- Where
- 2 sites in Belgium, Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Solvay Biologicals
Influenza
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Fluviral® (2012/2013 Season) in Adults
This study is designed to test the immunogenicity in terms of Hemagglutination Inhibition (HI) antibodies against each of the three vaccine influenza strains and reactogenicity and safety of Fluviral® containing the influenza…
- Trial name
- NCT01626820
- Testing
- Fluviral®
- Where
- Canada
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Ulcerative Colitis
A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis
This is a study to learn if the experimental medicine (called PF-07054894) is safe, effective, and how it is processed in adult people with ulcers in the colon.
- Trial name
- NCT05549323
- Testing
- PF-07054894
- Where
- 17 sites in United States, Germany and 1 more
- Volunteers
- 44 people
- Sponsor
- Pfizer
Orthomyxoviridae Infection, Influenza
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Compared to young adults, the elderly mount a lower antibody response to vaccination. Thus, improvement of the immune response to influenza vaccination in this age group, which is at higher risk for influenza-related morbidity…
- Conditions
- Orthomyxoviridae Infection, Influenza, Myxovirus Infection
- Trial name
- NCT00391053
- Testing
- High-Dose Inactivated, Split-Virion Influenza Vaccine, Inactivated, Split-Virion Influenza Vaccine
- Where
- 28 sites in United States
- Volunteers
- 3,851 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Attention-Deficit/Hyperactivity Disorder
Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate
This study will evaluate how long it takes for ADHD symptoms to improve in subjects who are judged by the Investigator to have had an inadequate response to methylphenidate therapy.
- Trial name
- NCT01106430
- Testing
- Lisdexamfetamine Dimesylate, Atomoxetine Hydrochloride
- Where
- 64 sites in United States, Belgium and 8 more
- Volunteers
- 267 people
- Sponsor
- Shire
Treatment, Osteoarthritis
Evaluate Safety & Efficacy of Condroflex in Subjects With OA
Primary Objective: To compare, after 12 weeks of double-blind treatment, the evolution of the improvement of pain (at rest and during / after exercise) in the questionnaire WOMAC (Western Ontario and McMaster Universities…
- Conditions
- Treatment, Osteoarthritis, Elderly
- Trial name
- ZD20108 (NCT00838487)
- Testing
- condroflex and exercise, sugar pill and exercise
- Where
- Brazil
- Volunteers
- 240 people
- Sponsor
- Zodiac Produtos Farmaceuticos S.A.
Hypercholesterolemia
Ezetimibe and Atorvastatin vs. Atorvastatin in Patients Age 65 and Older at High Risk for Coronary Heart Disease (CHD)(0653-112)
A 12 week clinical trial in patients 65 years of age and older with hypercholesterolemia at high risk for coronary heart disease to study the effects of atorvastatin and ezetimibe given in combination and two higher doses of…
- Trial name
- NCT00418834
- Testing
- ezetimibe and atorvastatin, atorvastatin
- Volunteers
- 1,053 people
- Sponsor
- Organon and Co
Influenza
Phase 3 Study of a H5N1 Vaccine in Adults, Elderly and Specified Risk Groups
The purpose of this study is to assess the safety and tolerability of, and the immune response to a non-adjuvanted H5N1 influenza vaccine in an adult and elderly population and in specified risk groups.
- Trial name
- NCT00711295
- Testing
- H5N1 Influenza Vaccine Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted
- Where
- 45 sites in Austria, Belgium and 5 more
- Volunteers
- 3,583 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Malaria
A Study to Evaluate the Safety, Immunogenicity and Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Malaria Vaccine RTS,S/AS02A, When Administered to Children Aged 1 to 4 Years Living in a Malaria-endemic Region of Mozambique.
Malaria is an important cause of death and serious illness among Mozambican children. Although the risk of malaria can be reduced by drugs and by impregnated bed nets, it would be helpful if children could be protected against…
- Trial name
- NCT00197041
- Testing
- RTS,S/AS02A
- Where
- Mozambique
- Volunteers
- 2,022 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Atopic Dermatitis
Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study that will enroll approximately 330 subjects aged 12 to 75 years old with moderate to severe atopic dermatitis.
- Trial name
- NCT04875169
- Testing
- Core Treatment Active Experimental: SHR0302 Dose#1, Core Treatment Active Experimental: SHR0302 Dose#2, Extension Treatment Active Experimental: SHR0302 Dose#1
- Where
- 52 sites in Canada, China
- Volunteers
- 336 people
- Sponsor
- Reistone Biopharma Company Limited
Influenza
A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2010/2011 Influenza Virus Strains for the Northern Hemisphere
A study to assess whether the Northern Hemisphere 2010/2011 season influenza vaccine Inflexal V fulfills the EMEA requirements for re-registration of influenza vaccines
- Trial name
- NCT01306305
- Testing
- Inflexal V
- Where
- Switzerland
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Asthma
A Dose-ranging Study of Fluticasone Furoate (FF)
This is a Phase IIb, multi-centre, stratified, randomised, double-blind, double-dummy, parallel-group, placebo and active controlled study in children aged 5-11 years with persistent uncontrolled asthma.
- Trial name
- NCT01563029
- Testing
- Fluticasone Furoate, Fluticasone Propionate
- Where
- 139 sites in United States, Bulgaria and 13 more
- Volunteers
- 597 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old
The primary objective of this study is to determine if there will be a greater mean reduction from baseline in glycated hemoglobin (HbA1c) achieved after 26 weeks of oral double-blind add-on therapy of dapagliflozin or…
- Trial name
- NCT03199053
- Testing
- Dapagliflozin, Saxagliptin
- Where
- 122 sites in United States, Argentina and 21 more
- Volunteers
- 256 people
- Sponsor
- AstraZeneca
COVID-19, SARS-CoV-2 Infection
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine SCTV01E-1 in Population Aged Above 18 Years
The study is a randomized, double-blind Phase II study. It will evaluate the immunogenicity and safety of SCTV01E-1. Approximately 400 participants aged 18 years and older will be enrolled in this study.
- Trial name
- NCT05522829
- Testing
- SCTV01E-1 on D0, SCTV01E-1 on D28, SCTV01E-1 on D150
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Norovirus Infections, Norwalk Gastroenteritis
Clinical Trial to Evaluate the Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine (Hansenula Polymorpha)
Phase II clinical study will explore dose and safety, immunogenicity in 4 age groups, including 18-59 years old group, 6-17 years old group, 3-5 years old group, 6-35 months old group, with a total of 1716 subjects.
- Trial name
- NCT04941261
- Testing
- middle-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine, high-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine
- Where
- China
- Volunteers
- 1,716 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
Human Papillomavirus Infection
Long-term Immune Persistence of a Bivalent HPV Vaccine in Females From Study 311-HPV-1004
This long-term extension study evaluates the persistence of neutralizing antibody responses to a bivalent human papillomavirus vaccine in females who previously participated in study 311-HPV-1004 (NCT02740777).
- Trial name
- NCT07820241
- Testing
- Bivalent Human Papillomavirus Vaccine (Types 16 and 18, Pichia pastoris)
- Where
- 2 sites in China
- Volunteers
- 348 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
SARS-CoV-2
A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19
The primary goal for this study is to evaluate the safety and reactogenicity of 3 dose levels of mRNA-1283 and 1 dose level of mRNA-1273 vaccine given to healthy adults in 2 doses, 28 days apart, and 1 dose level of mRNA-1283…
- Trial name
- NCT04813796
- Testing
- mRNA-1283, mRNA-1273
- Where
- 5 sites in United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Primary Insomnia
Elderly Primary Insomnia Polysomnographic Study (0928-002)(TERMINATED)
The purpose of the study is to test the safety and effectiveness of an Investigational Drug on insomnia in the elderly.
- Trial name
- NCT00094666
- Testing
- MK0928, gaboxadol / Duration of Treatment - 6 weeks
- Volunteers
- 465 people
- Sponsor
- H. Lundbeck A/S
Hemophilia A
A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab
This is an exploratory, single group, Phase 4, study to assess treatment with fitusiran prophylaxis after switching from emicizumab prophylaxis.
- Trial name
- NCT06145373
- Testing
- Fitusiran (SAR439774), Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC)
- Where
- 3 sites in United States, Taiwan
- Volunteers
- 20 people
- Sponsor
- Sanofi
Influenza
Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects
The present phase III study aims to evaluate the safety and immunogenicity of MF59-adjuvanted subunit seasonal influenza vaccine and to evaluate the consistency in the manufacturing process of three consecutive lots of…
- Trial name
- NCT01162122
- Testing
- MF59 adjuvanted trivalent subunit influenza vaccine (aTIV), Non-adjuvanted trivalent subunit influenza vaccine (TIV)
- Where
- 38 sites in United States, Colombia and 2 more
- Volunteers
- 7,109 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.